Cartherics is at the forefront of developing innovative immunotherapy treatments aimed at enhancing the body's immune response to combat various solid cancers. The company specializes in creating precisely-defined immunotherapy solutions by leveraging advanced technologies such as gene editing and Chimeric Antigen Receptor (CAR) technology. Their approach includes the use of induced pluripotent stem cells (iPSCs) to derive natural killer (NK) cells, which are genetically engineered to express CARs that target specific cancer markers, such as TAG-72. This method not only enhances the cytotoxic capabilities of these immune cells but also aims to overcome challenges associated with traditional therapies, such as immunosuppression and variability in treatment efficacy.

In addition to their allogeneic CAR-NK cell product, CTH-401, Cartherics is also advancing autologous CAR-T cell therapies, which utilize the patient's own T cells modified to better recognize and eliminate cancer cells. By employing techniques that delete genes responsible for immune suppression, these CAR-T cells are designed to be more effective in eradicating tumors, particularly in challenging cases like ovarian cancer. Cartherics is committed to expanding its pipeline of therapies, focusing on solid tumors and aiming to provide accessible, off-the-shelf treatment options that can significantly improve patient outcomes in the fight against cancer.

Australia

Cartherics works to create precisely-defined immunotherapy treatments to combat a variety of cancers. We take a multi-platform approach combining the best components of immune defences utilising gene editing and CAR technology. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Cartherics

Company Details